A broad spectrum of process development and manufacturing technology services are available from Dowpharma for the production of recombinant proteins, peptides, and vaccines from microbial hosts. Dowpharma’s Pfēnex Expression TechnologyTM, a Pseudomonas-based technology is built around specially designed strains of Pseudomonas fluorescens. Services include molecular biology, high-expression vector development, analytical method development, process development and process scale up. Dowpharma has a range of vaccine production technologies for antigens and adjuvant proteins ranging from peptide epitopes and virus-like particles (VLPs) to bacterial toxins and heteromultimers. All systems, including high-yield Pfēnex Expression Technology, are designed for cost effectiveness, rapid supply and scalability.
BD Biosciences is a life sciences leader with more than 50 years of expertise in cell biology products and services. The Advanced Bioprocessing strategic platform developed products currently being used as critical components in the production of some of the most widely used drugs and vaccines on the global market today. BD Biosciences - Advanced Bioprocessing is playing a major role in biopharmaceutical drug production, enabling customers to have a tremendous impact on the future of human healthcare. BD would like therefore to become an important partner for future biotech developments in Europe.
Merck is a global pharmaceutical and chemical company with sales of EUR 6.3 billion in 2006, a history that began in 1668, and a future shaped by 30,962 employees in 61 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
Miltenyi Bioprocess is the contract manufacturing division of Miltenyi Biotec GmbH. Founded in 1989, Miltenyi Biotec today has over 1.000 employees and is world market leader in magnetic cell separation products for research and therapeutic use. Miltenyi Biotec has manufactured products under GMP guidelines since the mid-nineties. Services include process development and cGMP production of recombinant APIs , aseptically vial filling and lyophilisation for peptides, proteins, plasmids (Class A) . Additional GMP services are: production of cell culture-and process-media, conjugation of peptides and proteins to different matrices, magnetic- and super-paramagnetic- beads. The company is running a complete independent infrastructure which covers QC, QA and RA.
Become a sponsor of this event, contact Sylvester Gabriel
|
